F40.0 F40.01 F40.1 F40.2 F41.0
Conditions
Interventions
Group 1: Intervention group = receives access to the internet-based support program after the baseline assessment
Group 2: Waitlist control group = receives no additional treatment in the interventio
receives access to the intervention after 12 weeks (after follow-up-assessment)
Sponsors
IVPNetworks GmbH
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: • One of the following diagnoses according to ICD-10 made by specialists or psychotherapists: F40.0x, F40.1, F40.2, F41.0 • Informed consent • Access to the Internet • Sufficient knowledge of the German language • Willingness to participate in three pseudonymized online surveys and willingness to independently use Novego - "Ängste überwinden"®. • Patients must be in a stable therapy situation (pharmacotherapy and/or psychotherapy or waiting situation) at least 4 weeks before randomization and should maintain this situation as far as possible during the study period.
Exclusion criteria
Exclusion criteria: • Presence of a psychotic or bipolar disorder (lifetime) • Acute suicidal behavior within the last 4 weeks • Dementia • Alcohol or substance dependence within the last 6 months • Current use of highly potent and/or atypical antipsychotics • Presence of a serious illness which, in the opinion of the investigator, precludes the patient's participation in the study until the end of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in anxiety symptomatology (sum score) at T1 compared to T0 as measured by the Beck Anxiety Inventory (BAI, Beck et al., 1988) | — |
Secondary
| Measure | Time frame |
|---|---|
| • Reduction in social anxiety symptomatology (sum score) at T1 compared to T0 as measured by the Liebowitz Social Anxiety Scale self-report (LSAS-SR; Baker et al., 2002) • Reduction in anxiety, depression, and stress symptomatology (sum score) at T1 compared to T0 as measured by the DASS-21 (Lovibond & Lovibond, 1995). • Increase in quality of life (mean score) at T1 compared to T0, as measured by the WHO-QOL-BREF (WHOQOL Group, 1998). • Increase in self-esteem (sum score) at T1 compared to T0, as measured by the RSES (Rosenberg, 1965) • Decrease in anxiety symptomatology (sum score) at T2 compared to T0, as measured by the Beck Anxiety Inventory (BAI, Beck et al., 1988) • Reduction in social anxiety symptomatology (sum score) at T2 compared to T0 as measured by the Liebowitz Social Anxiety Scale self-report (LSAS-SR; Baker et al., 2002) • Reduction in anxiety, depression, and stress symptomatology (sum score) at T2 compared to T0, as measured by the DASS-21 (Lovibond & Lovibond, 1995) • Increase in quality of life (mean score) at T2 compared to T0, as measured by the WHO-QOL-BREF (WHOQOL Group, 1998). • Increase in self-esteem (sum score) at T2 compared to T0 as measured by the RSES (Rosenberg, 1965). • Mean score of positive treatment expectancy at T0, as measured by the TEX-Q (Alberts et al., 2020) • Frequency of other positive and negative effects (including side effects) of the intervention at T1, as measured by the PANEPS-I (Baumeister & Moritz, 2022) • Presence of other common mental disorders at T0, assessed by the WSQ (Donker et al., 2009) • Satisfaction of the participants with the program at T1, measured by the ZUF-8 (Schmidt et al., 1989). • Influence of attitude toward online interventions at time point T0, as measured by the Attitude toward Psychological Online Interventions (APOI; Schröder et al., 2015). | — |
Countries
Germany
Contacts
Public ContactSteffen Moritz
Universitätsklinikum Hamburg-Eppendorf
Outcome results
None listed